Loomis Sayles & Co. L P Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Loomis Sayles & Co. L P lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 910,965 shares of the company’s stock after selling 34,302 shares during the period. Loomis Sayles & Co. L P owned about 1.07% of CRISPR Therapeutics worth $35,856,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of CRSP. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after acquiring an additional 372 shares in the last quarter. Congress Wealth Management LLC DE acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $222,000. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after buying an additional 10,579 shares in the last quarter. LPL Financial LLC boosted its stake in shares of CRISPR Therapeutics by 39.3% during the 4th quarter. LPL Financial LLC now owns 149,726 shares of the company’s stock worth $5,893,000 after acquiring an additional 42,232 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at about $634,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Down 2.9 %

NASDAQ:CRSP opened at $38.04 on Friday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $70.12. The stock’s fifty day moving average is $43.17 and its two-hundred day moving average is $45.23. The company has a market capitalization of $3.26 billion, a P/E ratio of -8.70 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Greene bought 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares in the company, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, March 21st. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Morgan Stanley boosted their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.